Back
75· Active
Health & Science1d 12h ago
A panel of outside experts voted unanimously that the benefits of Eli Lilly’s Alzheimer’s drug, donanemab, outweigh its risks for patients in early stages of the disease.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) Advisory Panel
What
A panel of outside experts voted unanimously that the benefits of Eli Lilly’s Alzheimer’s drug, donanemab, outweigh its risks for patients in early stages of the disease.
When
Sun, 07 Jun 2026 21:40:04 GMT · 1d 12h ago
Where
Silver Spring, Maryland, USA · 39.0350°N, 76.9950°W
Why
The decision follows clinical trial data showing the drug significantly slows cognitive and functional decline by targeting amyloid plaques in the brain.
The Frontline Impact
How this affects you
This clearing of a major regulatory hurdle suggests a third treatment option for Alzheimer's patients may soon be available on the market, potentially shifting standard care protocols.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.